Login Register Cart 0
Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Natural Product-based Therapies for Inflammatory Bowel Disease: Targeting Key Signaling Pathways

Author(s): Shifali Gupta, Sunny Kumar and Diksha Sharma*

Volume 25, Issue 22, 2025

Published on: 15 October, 2025

Page: [1716 - 1738] Pages: 23

DOI: 10.2174/0113895575405061250923110348

Abstract

Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn’s disease, accounts for chronic inflammation in the entire gastrointestinal tract. Conventional treatments, such as amino salicylates, corticosteroids, immunomodulators, and biologics, can all alleviate symptoms; however, they may cause unwanted side effects and are extremely expensive. Most of the time, long-term treatment is also less effective. This review aims to discuss natural products (NPs) with therapeutic potential for IBD, emphasizing flavonoids, terpenoids, polysaccharides, and alkaloids. The compounds have been chosen based on literature reporting antiinflammatory, antioxidative, and immunomodulatory activities that relate to IBD pathophysiology. Preclinical evidence using in vivo and in vitro models and available clinical data provides the basis for the main pharmacological effects, mechanisms of action, and safety profiles of these NPs. The key molecular pathways that are targeted include the NF-κB, MAPK, and JAK/STAT signaling pathways, as well as the establishment of the gut microbiota and intestinal barrier functions. Standardization, bioavailability, and maximal dosing remain challenging issues even when experimental models show promising results for various NPs. Hence, this review stresses the urgency for well-designed clinical trials and suitable formulation approaches to translate these observations into efficacious and evidence-based therapies. Being a natural remedy option, NPs could be considered complementary or alternative treatments for IBD, demanding further interrogation within an integrated therapeutic paradigm.

Keywords: Inflammatory bowel disease, natural products, flavonoids, polysaccharides, NF-κB inhibitor, MAPK modulator.

« Previous Next »
Graphical Abstract

[1]
Park, S.C.; Jeen, Y.T. Genetic studies of inflammatory bowel disease-focusing on Asian patients. Cells, 2019, 8(5), 404.
[http://dx.doi.org/10.3390/cells8050404] [PMID: 31052430]
[2]
Larabi, A.; Barnich, N.; Nguyen, H.T.T. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy, 2020, 16(1), 38-51.
[http://dx.doi.org/10.1080/15548627.2019.1635384] [PMID: 31286804]
[3]
Lee, M.; Chang, E.B. Inflammatory bowel diseases (IBD) and the microbiome—searching the crime scene for clues. Gastroenterology, 2021, 160(2), 524-537.
[http://dx.doi.org/10.1053/j.gastro.2020.09.056] [PMID: 33253681]
[4]
Alatab, S.; Sepanlou, S.G.; Ikuta, K.; Vahedi, H.; Bisignano, C.; Safiri, S.; Sadeghi, A.; Nixon, M.R.; Abdoli, A.; Abolhassani, H.; Alipour, V.; Almadi, M.A.H.; Almasi-Hashiani, A.; Anushiravani, A.; Arabloo, J.; Atique, S.; Awasthi, A.; Badawi, A.; Baig, A.A.A.; Bhala, N.; Bijani, A.; Biondi, A.; Borzì, A.M.; Burke, K.E.; Carvalho, F.; Daryani, A.; Dubey, M.; Eftekhari, A.; Fernandes, E.; Fernandes, J.C.; Fischer, F.; Haj-Mirzaian, A.; Haj-Mirzaian, A.; Hasanzadeh, A.; Hashemian, M.; Hay, S.I.; Hoang, C.L.; Househ, M.; Ilesanmi, O.S.; Jafari Balalami, N.; James, S.L.; Kengne, A.P.; Malekzadeh, M.M.; Merat, S.; Meretoja, T.J.; Mestrovic, T.; Mirrakhimov, E.M.; Mirzaei, H.; Mohammad, K.A.; Mokdad, A.H.; Monasta, L.; Negoi, I.; Nguyen, T.H.; Nguyen, C.T.; Pourshams, A.; Poustchi, H.; Rabiee, M.; Rabiee, N.; Ramezanzadeh, K.; Rawaf, D.L.; Rawaf, S.; Rezaei, N.; Robinson, S.R.; Ronfani, L.; Saxena, S.; Sepehrimanesh, M.; Shaikh, M.A.; Sharafi, Z.; Sharif, M.; Siabani, S.; Sima, A.R.; Singh, J.A.; Soheili, A.; Sotoudehmanesh, R.; Suleria, H.A.R.; Tesfay, B.E.; Tran, B.; Tsoi, D.; Vacante, M.; Wondmieneh, A.B.; Zarghi, A.; Zhang, Z-J.; Dirac, M.; Malekzadeh, R.; Naghavi, M. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol. Hepatol., 2020, 5(1), 17-30.GBD. 2017 Inflammatory Bowel Disease Collaborators.
[http://dx.doi.org/10.1016/S2468-1253(19)30333-4] [PMID: 31648971]
[5]
Molodecky, N.A.; Soon, I.S.; Rabi, D.M.; Ghali, W.A.; Ferris, M.; Chernoff, G.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Barkema, H.W.; Kaplan, G.G. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 2012, 142(1), 46-54.e42.
[http://dx.doi.org/10.1053/j.gastro.2011.10.001] [PMID: 22001864]
[6]
Mak, W.Y.; Zhao, M.; Ng, S.C.; Burisch, J. The epidemiology of inflammatory bowel disease: East meets west. J. Gastroenterol. Hepatol., 2020, 35(3), 380-389.
[http://dx.doi.org/10.1111/jgh.14872] [PMID: 31596960]
[7]
Kotze, P.G.; Underwood, F.E.; Damião, A.O.M.C.; Ferraz, J.G.P.; Saad-Hossne, R.; Toro, M.; Iade, B.; Bosques-Padilla, F.; Teixeira, F.V.; Juliao-Banos, F.; Simian, D.; Ghosh, S.; Panaccione, R.; Ng, S.C.; Kaplan, G.G. Progression of inflammatory bowel diseases throughout Latin America and the Caribbean: A systematic review. Clin. Gastroenterol. Hepatol., 2020, 18(2), 304-312.
[http://dx.doi.org/10.1016/j.cgh.2019.06.030] [PMID: 31252191]
[8]
Verstockt, B.; Ferrante, M.; Vermeire, S.; Van Assche, G. New treatment options for inflammatory bowel diseases. J. Gastroenterol., 2018, 53(5), 585-590.
[http://dx.doi.org/10.1007/s00535-018-1449-z] [PMID: 29556726]
[9]
Kennedy, N.A.; Heap, G.A.; Green, H.D.; Hamilton, B.; Bewshea, C.; Walker, G.J.; Thomas, A.; Nice, R.; Perry, M.H.; Bouri, S.; Chanchlani, N.; Heerasing, N.M.; Hendy, P.; Lin, S.; Gaya, D.R.; Cummings, J.R.F.; Selinger, C.P.; Lees, C.W.; Hart, A.L.; Parkes, M.; Sebastian, S.; Mansfield, J.C.; Irving, P.M.; Lindsay, J.; Russell, R.K.; McDonald, T.J.; McGovern, D.; Goodhand, J.R.; Ahmad, T.; Patel, V.; Mazhar, Z.; Saich, R.; Colleypriest, B.; Tham, T.C.; Iqbal, T.H.; Kaushik, V.; Murugesan, S.; Singh, S.; Weaver, S.; Preston, C.; Butt, A.; Smith, M.; Basude, D.; Beale, A.; Langlands, S.; Direkze, N.; Parkes, M.; Torrente, F.; De La Revella Negro, J.; MacDonald, C.E.; Evans, S.M.; Gunasekera, A.V.J.; Thakur, A.; Elphick, D.; Shenoy, A.; Nwokolo, C.U.; Dhar, A.; Cole, A.T.; Agrawal, A.; Bridger, S.; Doherty, J.; Cooper, S.C.; de Silva, S.; Mowat, C.; Mayhead, P.; Lees, C.; Jones, G.; Ahmad, T.; Hart, J.W.; Gaya, D.R.; Russell, R.K.; Gervais, L.; Dunckley, P.; Mahmood, T.; Banim, P.J.R.; Sonwalkar, S.; Ghosh, D.; Phillips, R.H.; Azaz, A.; Sebastian, S.; Shenderey, R.; Armstrong, L.; Bell, C.; Hariraj, R.; Matthews, H.; Jafferbhoy, H.; Selinger, C.P.; Zamvar, V.; De Caestecker, J.S.; Willmott, A.; Miller, R.; Babu, P.S.; Tzivinikos, C.; Bloom, S.L.; Chung-Faye, G.; Croft, N.M.; Fell, J.M.E.; Harbord, M.; Hart, A.; Hope, B.; Irving, P.M.; Lindsay, J.O.; Mawdsley, J.E.; McNair, A.; Monahan, K.J.; Murray, C.D.; Orchard, T.; Paul, T.; Pollok, R.; Shah, N.; Bouri, S.; Johnson, M.W.; Modi, A.; Kabiru, K.D.; Baburajan, B.K.; Bhaduri, B.; Fagbemi, A.A.; Levison, S.; Limdi, J.K.; Watts, G.; Foley, S.; Ramadas, A.; MacFaul, G.; Mansfield, J.; Grellier, L.; Morris, M-A.; Tremelling, M.; Hawkey, C.; Kirkham, S.; Charlton, C.P.J.; Rodrigues, A.; Simmons, A.; Lewis, S.J.; Snook, J.; Tighe, M.; Goggin, P.M.; De Silva, A.N.; Lal, S.; Smith, M.S.; Panter, S.; Cummings, J.R.F.; Dharmisari, S.; Carter, M.; Watts, D.; Mahmood, Z.; McLain, B.; Sen, S.; Pigott, A.J.; Hobday, D.; Wesley, E.; Johnston, R.; Edwards, C.; Beckly, J.; Vani, D.; Ramakrishnan, S.; Chaudhary, R.; Trudgill, N.J.; Cooney, R.; Bell, A.; Prasad, N.; Gordon, J.N.; Brookes, M.J.; Li, A.; Gore, S. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: A prospective, multicentre, cohort study. Lancet Gastroenterol. Hepatol., 2019, 4(5), 341-353. UK Inflammatory Bowel Disease Pharmacogenetics Study Group.
[http://dx.doi.org/10.1016/S2468-1253(19)30012-3] [PMID: 30824404]
[10]
Danese, S.; Furfaro, F.; Vetrano, S. Targeting S1P in inflammatory bowel disease: new avenues for modulating intestinal leukocyte migration. J. Crohn’s Colitis, 2018, 12(Suppl. 2), S678-S686.
[http://dx.doi.org/10.1093/ecco-jcc/jjx107] [PMID: 28961752]
[11]
Zaidun, N.H.; Thent, Z.C.; Latiff, A.A. Combating oxidative stress disorders with citrus flavonoid: Naringenin. Life Sci., 2018, 208, 111-122.
[http://dx.doi.org/10.1016/j.lfs.2018.07.017] [PMID: 30021118]
[12]
Den Hartogh, D.J.; Tsiani, E. Antidiabetic properties of naringenin: A citrus fruit polyphenol. Biomolecules, 2019, 9(3), 99.
[http://dx.doi.org/10.3390/biom9030099] [PMID: 30871083]
[13]
Pinho-Ribeiro, F.A.; Zarpelon, A.C.; Fattori, V.; Manchope, M.F.; Mizokami, S.S.; Casagrande, R.; Verri, W.A. Naringenin reduces inflammatory pain in mice. Neuropharmacology, 2016, 105, 508-519.
[http://dx.doi.org/10.1016/j.neuropharm.2016.02.019] [PMID: 26907804]
[14]
Zeng, W.; Jin, L.; Zhang, F.; Zhang, C.; Liang, W. Naringenin as a potential immunomodulator in therapeutics. Pharmacol. Res., 2018, 135, 122-126.
[http://dx.doi.org/10.1016/j.phrs.2018.08.002] [PMID: 30081177]
[15]
Zobeiri, M.; Belwal, T.; Parvizi, F.; Naseri, R.; Farzaei, M.H.; Nabavi, S.F.; Sureda, A.; Nabavi, S.M. Naringenin and its nano-formulations for fatty liver: Cellular modes of action and clinical perspective. Curr. Pharm. Biotechnol., 2018, 19(3), 196-205.
[http://dx.doi.org/10.2174/1389201019666180514170122] [PMID: 29766801]
[16]
Dou, W.; Zhang, J.; Sun, A.; Zhang, E.; Ding, L.; Mukherjee, S.; Wei, X.; Chou, G.; Wang, Z.T.; Mani, S. Protective effect of naringenin against experimental colitis via suppression of toll-like receptor 4/NF-κB signalling. Br. J. Nutr., 2013, 110(4), 599-608.
[http://dx.doi.org/10.1017/S0007114512005594] [PMID: 23506745]
[17]
Fathima, A.; Rao, J.R. Selective toxicity of Catechin—A natural flavonoid towards bacteria. Appl. Microbiol. Biotechnol., 2016, 100(14), 6395-6402.
[http://dx.doi.org/10.1007/s00253-016-7492-x] [PMID: 27052380]
[18]
Martínez Leal, J.; Valenzuela Suárez, L.; Jayabalan, R.; Huerta Oros, J.; Escalante-Aburto, A. A review on health benefits of kombucha nutritional compounds and metabolites. CYTA J. Food, 2018, 16(1), 390-399.
[http://dx.doi.org/10.1080/19476337.2017.1410499]
[19]
Cardoso, R.R.; Neto, R.O.; dos Santos D’Almeida, C.T.; do Nascimento, T.P.; Pressete, C.G.; Azevedo, L.; Martino, H.S.D.; Cameron, L.C.; Ferreira, M.S.L.; Barros, F.A.R. Kombuchas from green and black teas have different phenolic profile, which impacts their antioxidant capacities, antibacterial and antiproliferative activities. Food Res. Int., 2020, 128, 108782.
[http://dx.doi.org/10.1016/j.foodres.2019.108782] [PMID: 31955755]
[20]
Mascia, C.; Maina, M.; Chiarpotto, E.; Leonarduzzi, G.; Poli, G.; Biasi, F. Proinflammatory effect of cholesterol and its oxidation products on CaCo-2 human enterocyte-like cells: Effective protection by epigallocatechin-3-gallate. Free Radic. Biol. Med., 2010, 49(12), 2049-2057.
[http://dx.doi.org/10.1016/j.freeradbiomed.2010.09.033] [PMID: 20923702]
[21]
Sergent, T.; Piront, N.; Meurice, J.; Toussaint, O.; Schneider, Y.J. Anti-inflammatory effects of dietary phenolic compounds in an in vitro model of inflamed human intestinal epithelium. Chem. Biol. Interact., 2010, 188(3), 659-667.
[http://dx.doi.org/10.1016/j.cbi.2010.08.007] [PMID: 20816778]
[22]
Bing, X.; Xuelei, L.; Wanwei, D.; Linlang, L.; Keyan, C. EGCG maintains Th1/Th2 balance and mitigates ulcerative colitis induced by dextran sulfate sodium through TLR4/MyD88/NF‐κB signaling pathway in rats. Can. J. Gastroenterol. Hepatol., 2017, 2017(1), 1-9.
[http://dx.doi.org/10.1155/2017/3057268] [PMID: 29404307]
[23]
Chen, Y.; Le, T.H.; Du, Q.; Zhao, Z.; Liu, Y.; Zou, J.; Hua, W.; Liu, C.; Zhu, Y. Genistein protects against DSS-induced colitis by inhibiting NLRP3 inflammasome via TGR5-cAMP signaling. Int. Immunopharmacol., 2019, 71, 144-154.
[http://dx.doi.org/10.1016/j.intimp.2019.01.021] [PMID: 30901677]
[24]
Xue, B.; Xie, J.; Huang, J.; Chen, L.; Gao, L.; Ou, S.; Wang, Y.; Peng, X. Plant polyphenols alter a pathway of energy metabolism by inhibiting fecal Bacteroidetes and Firmicutes in vitro. Food Funct., 2016, 7(3), 1501-1507.
[http://dx.doi.org/10.1039/C5FO01438G] [PMID: 26882962]
[25]
Bitzer, Z.T.; Elias, R.J.; Vijay-Kumar, M.; Lambert, J.D. (‐)‐Epigallocatechin‐3‐gallate decreases colonic inflammation and permeability in a mouse model of colitis, but reduces macronutrient digestion and exacerbates weight loss. Mol. Nutr. Food Res., 2016, 60(10), 2267-2274.
[http://dx.doi.org/10.1002/mnfr.201501042] [PMID: 27218415]
[26]
Guan, F.; Liu, A.B.; Li, G.; Yang, Z.; Sun, Y.; Yang, C.S.; Ju, J. Deleterious effects of high concentrations of (-)-epigallocatechin-3-gallate and atorvastatin in mice with colon inflammation. Nutr. Cancer, 2012, 64(6), 847-855.
[http://dx.doi.org/10.1080/01635581.2012.695424] [PMID: 22716294]
[27]
Dryden, G.W.; Lam, A.; Beatty, K.; Qazzaz, H.H.; McClain, C.J. A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis. Inflamm. Bowel Dis., 2013, 19(9), 1.
[http://dx.doi.org/10.1097/MIB.0b013e31828f5198] [PMID: 23846486]
[28]
Liu, D.; Wu, J.; Xie, H.; Liu, M.; Takau, I.; Zhang, H.; Xiong, Y.; Xia, C. Inhibitory effect of hesperetin and on human UDP-glucuronosyltransferase enzymes: Implications for herb–drug interactions. Biol. Pharm. Bull., 2016, 39(12), 2052-2059.
[http://dx.doi.org/10.1248/bpb.b16-00581] [PMID: 27904048]
[29]
Shirzad, M.; Heidarian, E.; Beshkar, P.; Gholami-Arjenaki, M. Biological effects of hesperetin on interleukin-6/phosphorylated signal transducer and activator of transcription 3 pathway signaling in prostate cancer PC3 cells. Pharmacognosy Res., 2017, 9(2), 188-194.
[PMID: 28539744]
[30]
González-Alfonso, J.; Míguez, N.; Padilla, J.; Leemans, L.; Poveda, A.; Jiménez-Barbero, J.; Ballesteros, A.; Sandoval, G.; Plou, F. Optimization of regioselective α-glucosylation of hesperetin catalyzed by cyclodextrin glucanotransferase. Molecules, 2018, 23(11), 2885.
[http://dx.doi.org/10.3390/molecules23112885] [PMID: 30400664]
[31]
Parhiz, H.; Roohbakhsh, A.; Soltani, F.; Rezaee, R.; Iranshahi, M. Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and hesperetin: An updated review of their molecular mechanisms and experimental models. Phytother. Res., 2015, 29(3), 323-331.
[http://dx.doi.org/10.1002/ptr.5256] [PMID: 25394264]
[32]
Alu’datt, M.H.; Rababah, T.; Alhamad, M.N.; Al-Mahasneh, M.A.; Ereifej, K.; Al-Karaki, G.; Al-Duais, M.; Andrade, J.E.; Tranchant, C.C.; Kubow, S.; Ghozlan, K.A. Profiles of free and bound phenolics extracted from Citrus fruits and their roles in biological systems: Content, and antioxidant, anti-diabetic and anti-hypertensive properties. Food Funct., 2017, 8(9), 3187-3197.
[http://dx.doi.org/10.1039/C7FO00212B] [PMID: 28805834]
[33]
Chen, F.; Yin, Y.; Liu, Y.; Liu, X.; Liu, F.; Zhang, X.; Zhao, H.; Liu, D. Oxymatrine alleviates the inflammatory damage and its mechanism in rats with TNBS-induced colitis. Xi bao yu fen zi Mian yi xue za zhi= Chinese. J. Cell. Mol. Immunol., 2019, 35(1), 1-5.
[34]
Li, Q.; Miao, Z.; Wang, R.; Yang, J.; Zhang, D. Hesperetin induces apoptosis in human glioblastoma cells via p38 MAPK activation. Nutr. Cancer, 2020, 72(3), 538-545.
[http://dx.doi.org/10.1080/01635581.2019.1638424] [PMID: 31295040]
[35]
Elhennawy, M.G.; Abdelaleem, E.A.; Zaki, A.A.; Mohamed, W.R. Cinnamaldehyde and hesperetin attenuate TNBS‐induced ulcerative colitis in rats through modulation of the JAk2/STAT3/SOCS3 pathway. J. Biochem. Mol. Toxicol., 2021, 35(5), e22730.
[http://dx.doi.org/10.1002/jbt.22730] [PMID: 33522063]
[36]
Polat, F.R.; Karaboğa, I.; Polat, M.S.; Erboğa, Z.; Yilmaz, A.; Güzel, S. Effect of hesperetin on inflammatory and oxidative status in trinitrobenzene sulfonic acid-induced experimental colitis model. Cell. Mol. Biol., 2018, 64(11), 58-65.
[http://dx.doi.org/10.14715/cmb/2018.64.11.11] [PMID: 30213290]
[37]
Guazelli, C.F.S.; Fattori, V.; Ferraz, C.R.; Borghi, S.M.; Casagrande, R.; Baracat, M.M.; Verri, W.A. Antioxidant and anti-inflammatory effects of hesperidin methyl chalcone in experimental ulcerative colitis. Chem. Biol. Interact., 2021, 333, 109315.
[http://dx.doi.org/10.1016/j.cbi.2020.109315] [PMID: 33171134]
[38]
Erlund, I.; Meririnne, E.; Alfthan, G.; Aro, A. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J. Nutr., 2001, 131(2), 235-241.
[http://dx.doi.org/10.1093/jn/131.2.235] [PMID: 11160539]
[39]
Ganai, A.A.; Farooqi, H. Bioactivity of genistein: A review of in vitro and in vivo studies. Biomed. Pharmacother., 2015, 76, 30-38.
[http://dx.doi.org/10.1016/j.biopha.2015.10.026] [PMID: 26653547]
[40]
Sahin, I.; Bilir, B.; Ali, S.; Sahin, K.; Kucuk, O. Soy isoflavones in integrative oncology: Increased efficacy and decreased toxicity of cancer therapy. Integr. Cancer Ther., 2019, 18, 1534735419835310.
[http://dx.doi.org/10.1177/1534735419835310] [PMID: 30897972]
[41]
Sefrina, L.R.; Briawan, D.; Sinaga, T.; Permaesih, D. Flavonoid database based on Indonesian foods. J. Nutr. Sci. Vitaminol., 2020, 66(Suppl.), S251-S255.
[http://dx.doi.org/10.3177/jnsv.66.S251] [PMID: 33612606]
[42]
Spagnuolo, C.; Russo, G.L.; Orhan, I.E.; Habtemariam, S.; Daglia, M.; Sureda, A.; Nabavi, S.F.; Devi, K.P.; Loizzo, M.R.; Tundis, R.; Nabavi, S.M. Genistein and cancer: Current status, challenges, and future directions. Adv. Nutr., 2015, 6(4), 408-419.
[http://dx.doi.org/10.3945/an.114.008052] [PMID: 26178025]
[43]
Chen, Q.; Duan, X.; Fan, H.; Xu, M.; Tang, Q.; Zhang, L.; Shou, Z.; Liu, X.; Zuo, D.; Yang, J.; Deng, S.; Dong, Y.; Wu, H.; Liu, Y.; Nan, Z. Oxymatrine protects against DSS-induced colitis via inhibiting the PI3K/AKT signaling pathway. Int. Immunopharmacol., 2017, 53, 149-157.
[http://dx.doi.org/10.1016/j.intimp.2017.10.025] [PMID: 29107215]
[44]
Abron, J.D.; Singh, N.P.; Price, R.L.; Nagarkatti, M.; Nagarkatti, P.S.; Singh, U.P. Genistein induces macrophage polarization and systemic cytokine to ameliorate experimental colitis. PLoS One, 2018, 13(7), e0199631.
[http://dx.doi.org/10.1371/journal.pone.0199631] [PMID: 30024891]
[45]
Cao, W.; Kayama, H.; Chen, M.L.; Delmas, A.; Sun, A.; Kim, S.Y.; Rangarajan, E.S.; McKevitt, K.; Beck, A.P.; Jackson, C.B.; Crynen, G.; Oikonomopoulos, A.; Lacey, P.N.; Martinez, G.J.; Izard, T.; Lorenz, R.G.; Rodriguez-Palacios, A.; Cominelli, F.; Abreu, M.T.; Hommes, D.W.; Koralov, S.B.; Takeda, K.; Sundrud, M.S. The xenobiotic transporter Mdr1 enforces T cell homeostasis in the presence of intestinal bile acids. Immunity, 2017, 47(6), 1182-1196.e10.
[http://dx.doi.org/10.1016/j.immuni.2017.11.012] [PMID: 29262351]
[46]
Schneider, L.S.; Hernandez, G.; Zhao, L.; Franke, A.A.; Chen, Y.L.; Pawluczyk, S.; Mack, W.J.; Brinton, R.D. Safety and feasibility of estrogen receptor-β targeted phytoSERM formulation for menopausal symptoms: Phase 1b/2a randomized clinical trial. Menopause, 2019, 26(8), 874-884.
[http://dx.doi.org/10.1097/GME.0000000000001325] [PMID: 30889096]
[47]
Jaakola, L. New insights into the regulation of anthocyanin biosynthesis in fruits. Trends Plant Sci., 2013, 18(9), 477-483.
[http://dx.doi.org/10.1016/j.tplants.2013.06.003] [PMID: 23870661]
[48]
Sui, X.; Zhang, Y.; Zhou, W. Bread fortified with anthocyanin-rich extract from black rice as nutraceutical sources: Its quality attributes and in vitro digestibility. Food Chem., 2016, 196, 910-916.
[http://dx.doi.org/10.1016/j.foodchem.2015.09.113] [PMID: 26593572]
[49]
Silva, S.; Costa, E.M.; Calhau, C.; Morais, R.M.; Pintado, M.E. Anthocyanin extraction from plant tissues: A review. Crit. Rev. Food Sci. Nutr., 2017, 57(14), 3072-3083.
[http://dx.doi.org/10.1080/10408398.2015.1087963] [PMID: 26529399]
[50]
Fang, J. Bioavailability of anthocyanins. Drug Metab. Rev., 2014, 46(4), 508-520.
[http://dx.doi.org/10.3109/03602532.2014.978080] [PMID: 25347327]
[51]
Chun, O.K.; Chung, S.J.; Song, W.O. Estimated dietary flavonoid intake and major food sources of U.S. adults. J. Nutr., 2007, 137(5), 1244-1252.
[http://dx.doi.org/10.1093/jn/137.5.1244] [PMID: 17449588]
[52]
Del Rio, D.; Borges, G.; Crozier, A. Berry flavonoids and phenolics: Bioavailability and evidence of protective effects. Br. J. Nutr., 2010, 104(S3), S67-S90.
[http://dx.doi.org/10.1017/S0007114510003958] [PMID: 20955651]
[53]
Sharma, P.; McClees, S.; Afaq, F. Pomegranate for prevention and treatment of cancer: An update. Molecules, 2017, 22(1), 177.
[http://dx.doi.org/10.3390/molecules22010177] [PMID: 28125044]
[54]
Thumann, T.A.; Pferschy-Wenzig, E.M.; Moissl-Eichinger, C.; Bauer, R. The role of gut microbiota for the activity of medicinal plants traditionally used in the European Union for gastrointestinal disorders. J. Ethnopharmacol., 2019, 245, 112153.
[http://dx.doi.org/10.1016/j.jep.2019.112153] [PMID: 31408679]
[55]
Tian, L.; Tan, Y.; Chen, G.; Wang, G.; Sun, J.; Ou, S.; Chen, W.; Bai, W. Metabolism of anthocyanins and consequent effects on the gut microbiota. Crit. Rev. Food Sci. Nutr., 2019, 59(6), 982-991.
[http://dx.doi.org/10.1080/10408398.2018.1533517] [PMID: 30595029]
[56]
Khan, M.S.; Ikram, M.; Park, J.S.; Park, T.J.; Kim, M.O. Gut microbiota, its role in induction of Alzheimer’s disease pathology, and possible therapeutic interventions: Special focus on anthocyanins. Cells, 2020, 9(4), 853.
[http://dx.doi.org/10.3390/cells9040853] [PMID: 32244729]
[57]
Peng, Y.; Yan, Y.; Wan, P.; Chen, D.; Ding, Y.; Ran, L.; Mi, J.; Lu, L.; Zhang, Z.; Li, X.; Zeng, X.; Cao, Y. Gut microbiota modulation and anti-inflammatory properties of anthocyanins from the fruits of Lycium ruthenicum Murray in dextran sodium sulfate-induced colitis in mice. Free Radic. Biol. Med., 2019, 136, 96-108.
[http://dx.doi.org/10.1016/j.freeradbiomed.2019.04.005] [PMID: 30959170]
[58]
Wu, L.H.; Xu, Z.L.; Dong, D.; He, S.A.; Yu, H. Protective effect of anthocyanins extract from blueberry on TNBS‐induced IBD model of mice. Evid. Based Complement. Alternat. Med., 2011, 2011(1), 525462.
[http://dx.doi.org/10.1093/ecam/neq040] [PMID: 21785630]
[59]
Piberger, H.; Oehme, A.; Hofmann, C.; Dreiseitel, A.; Sand, P.G.; Obermeier, F.; Schoelmerich, J.; Schreier, P.; Krammer, G.; Rogler, G. Bilberries and their anthocyanins ameliorate experimental colitis. Mol. Nutr. Food Res., 2011, 55(11), 1724-1729.
[http://dx.doi.org/10.1002/mnfr.201100380] [PMID: 21957076]
[60]
Jiao, Y.F.; Lu, M.; Zhao, Y.P.; Liu, N.; Niu, Y.T.; Niu, Y.; Zhou, R.; Yu, J.Q. N-methylcytisine ameliorates dextran-sulfate-sodium-induced colitis in mice by inhibiting the inflammatory response. Molecules, 2018, 23(3), 510.
[http://dx.doi.org/10.3390/molecules23030510] [PMID: 29495327]
[61]
Nomi, Y.; Iwasaki-Kurashige, K.; Matsumoto, H. Therapeutic effects of anthocyanins for vision and eye health. Molecules, 2019, 24(18), 3311.
[http://dx.doi.org/10.3390/molecules24183311] [PMID: 31514422]
[62]
Lai, Y.; Zeng, H.; He, M.; Qian, H.; Wu, Z.; Luo, Z.; Xue, Y.; Yao, G.; Zhang, Y. 6,8-Di-C-methyl-flavonoids with neuroprotective activities from Rhododendron fortunei. Fitoterapia, 2016, 112, 237-243.
[http://dx.doi.org/10.1016/j.fitote.2016.06.008] [PMID: 27345941]
[63]
Nishitani, Y.; Yamamoto, K.; Yoshida, M.; Azuma, T.; Kanazawa, K.; Hashimoto, T.; Mizuno, M. Intestinal anti‐inflammatory activity of luteolin: Role of the aglycone in NF‐κB inactivation in macrophages co‐cultured with intestinal epithelial cells. Biofactors, 2013, 39(5), 522-533.
[http://dx.doi.org/10.1002/biof.1091] [PMID: 23460110]
[64]
Ran, X.; Li, Y.; Chen, G.; Fu, S.; He, D.; Huang, B.; Wei, L.; Lin, Y.; Guo, Y.; Hu, G. Farrerol ameliorates TNBS-induced colonic inflammation by inhibiting ERK1/2, JNK1/2, and NF-κB signaling pathway. Int. J. Mol. Sci., 2018, 19(7), 2037.
[http://dx.doi.org/10.3390/ijms19072037] [PMID: 30011811]
[65]
Shi, H.J.; Song, H.B.; Wang, L.; Xiao, S.X.; Bo, K.P.; Ma, W. The synergy of diammonium glycyrrhizinate remarkably reduces the toxicity of oxymatrine in ICR mice. Biomed. Pharmacother., 2018, 97, 19-25.
[http://dx.doi.org/10.1016/j.biopha.2017.09.039] [PMID: 29080454]
[66]
Tao, F.; Qian, C.; Guo, W.; Luo, Q.; Xu, Q.; Sun, Y. Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin. Biochem. Pharmacol., 2013, 85(6), 798-807.
[http://dx.doi.org/10.1016/j.bcp.2012.12.002] [PMID: 23261528]
[67]
Ju, S.; Ge, Y.; Li, P.; Tian, X.; Wang, H.; Zheng, X.; Ju, S. Dietary quercetin ameliorates experimental colitis in mouse by remodeling the function of colonic macrophages via a heme oxygenase-1-dependent pathway. Cell Cycle, 2018, 17(1), 53-63.
[http://dx.doi.org/10.1080/15384101.2017.1387701] [PMID: 28976231]
[68]
He, C.; Wang, Z.; Shi, J. Pharmacological effects of icariin. Adv. Pharmacol., 2020, 87, 179-203.
[http://dx.doi.org/10.1016/bs.apha.2019.10.004] [PMID: 32089233]
[69]
Huang, Y.; Xing, K.; Qiu, L.; Wu, Q.; Wei, H. Therapeutic implications of functional tea ingredients for ameliorating inflammatory bowel disease: A focused review. Crit. Rev. Food Sci. Nutr., 2022, 62(19), 5307-5321.
[http://dx.doi.org/10.1080/10408398.2021.1884532] [PMID: 33635174]
[70]
Liu, C.; Wang, J.; Yang, Y.; Liu, X.; Zhu, Y.; Zou, J.; Peng, S.; Le, T.H.; Chen, Y.; Zhao, S.; He, B.; Mi, Q.; Zhang, X.; Du, Q. Ginsenoside Rd ameliorates colitis by inducing p62-driven mitophagy-mediated NLRP3 inflammasome inactivation in mice. Biochem. Pharmacol., 2018, 155, 366-379.
[http://dx.doi.org/10.1016/j.bcp.2018.07.010] [PMID: 30012462]
[71]
Kim, J.K.; Kim, J.Y.; Jang, S.E.; Choi, M.S.; Jang, H.M.; Yoo, H.H.; Kim, D.H. Fermented red ginseng alleviates cyclophosphamide-induced immunosuppression and 2, 4, 6-trinitrobenzenesulfonic acid-induced colitis in mice by regulating macrophage activation and T cell differentiation. Am. J. Chin. Med., 2018, 46(8), 1879-1897.
[http://dx.doi.org/10.1142/S0192415X18500945] [PMID: 30518233]
[72]
Xu, L.; Zhang, Y.; Xue, X.; Liu, J.; Li, Z.S.; Yang, G.Y.; Song, Y.; Pan, Y.; Ma, Y.; Hu, S.; Wen, A.; Jia, Y.; Rodriguez, L.M.; Tull, M.B.; Benante, K.; Khan, S.A.; Cao, Y.; Jovanovic, B.; Richmond, E.; Umar, A.; Bergan, R.; Wu, K. A phase I trial of berberine in Chinese with ulcerative colitis. Cancer Prev. Res., 2020, 13(1), 117-126.
[http://dx.doi.org/10.1158/1940-6207.CAPR-19-0258] [PMID: 31619442]
[73]
Lee, S.Y.; Jeong, J.J.; Eun, S.H.; Kim, D.H. Anti-inflammatory effects of ginsenoside Rg1 and its metabolites ginsenoside Rh1 and 20(S)-protopanaxatriol in mice with TNBS-induced colitis. Eur. J. Pharmacol., 2015, 762, 333-343.
[http://dx.doi.org/10.1016/j.ejphar.2015.06.011] [PMID: 26054809]
[74]
Ryuk, J.A.; Zheng, M.S.; Lee, M.Y.; Seo, C.S.; Li, Y.; Lee, S.H.; Moon, D.C.; Lee, H.W.; Lee, J.H.; Park, J.Y.; Son, J.K.; Ko, B.S. Discrimination of Phellodendron amurense and P. chinense based on DNA analysis and the simultaneous analysis of alkaloids. Arch. Pharm. Res., 2012, 35(6), 1045-1054.
[http://dx.doi.org/10.1007/s12272-012-0612-y] [PMID: 22870814]
[75]
Ye, H.; Wu, Q.; Zhu, Y.; Guo, C.; Zheng, X. Ginsenoside Rh2 alleviates dextran sulfate sodium-induced colitis via augmenting TGFβ signaling. Mol. Biol. Rep., 2014, 41(8), 5485-5490.
[http://dx.doi.org/10.1007/s11033-014-3422-0] [PMID: 24893598]
[76]
Tian, M.; Ma, P.; Zhang, Y.; Mi, Y.; Fan, D. Ginsenoside Rk3 alleviated DSS-induced ulcerative colitis by protecting colon barrier and inhibiting NLRP3 inflammasome pathway. Int. Immunopharmacol., 2020, 85, 106645.
[http://dx.doi.org/10.1016/j.intimp.2020.106645] [PMID: 32521491]
[77]
Joh, E.H.; Lee, I.A.; Jung, I.H.; Kim, D.H. Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation—The key step of inflammation. Biochem. Pharmacol., 2011, 82(3), 278-286.
[http://dx.doi.org/10.1016/j.bcp.2011.05.003] [PMID: 21600888]
[78]
Yang, N.; Liang, G.; Lin, J.; Zhang, S.; Lin, Q.; Ji, X.; Chen, H.; Li, N.; Jin, S. Ginsenoside Rd therapy improves histological and functional recovery in a rat model of inflammatory bowel disease. Phytother. Res., 2020, 34(11), 3019-3028.
[http://dx.doi.org/10.1002/ptr.6734] [PMID: 32468636]
[79]
Zhang, A.; Wang, H.; Sun, H.; Zhang, Y.; An, N.; Yan, G.; Meng, X.; Wang, X. Metabolomics strategy reveals therapeutical assessment of limonin on nonbacterial prostatitis. Food Funct., 2015, 6(11), 3540-3549.
[http://dx.doi.org/10.1039/C5FO00489F] [PMID: 26302114]
[80]
Cui, H.; Cai, Y.; Wang, L.; Jia, B.; Li, J.; Zhao, S.; Chu, X.; Lin, J.; Zhang, X.; Bian, Y.; Zhuang, P. Berberine regulates Treg/Th17 balance to treat ulcerative colitis through modulating the gut microbiota in the colon. Front. Pharmacol., 2018, 9, 571.
[http://dx.doi.org/10.3389/fphar.2018.00571] [PMID: 29904348]
[81]
Fan, S.; Zhang, C.; Luo, T.; Wang, J.; Tang, Y.; Chen, Z.; Yu, L. Limonin: A review of its pharmacology, toxicity, and pharmacokinetics. Molecules, 2019, 24(20), 3679.
[http://dx.doi.org/10.3390/molecules24203679] [PMID: 31614806]
[82]
Liu, S.; Zhang, S.; Lv, X.; Lu, J.; Ren, C.; Zeng, Z.; Zheng, L.; Zhou, X.; Fu, H.; Zhou, D.; Chen, Y. Limonin ameliorates ulcerative colitis by regulating STAT3/miR-214 signaling pathway. Int. Immunopharmacol., 2019, 75, 105768.
[http://dx.doi.org/10.1016/j.intimp.2019.105768] [PMID: 31382166]
[83]
Chrzanowski, J.; Chrzanowska, A.; Graboń, W. Glycyrrhizin: An old weapon against a novel coronavirus. Phytother. Res., 2021, 35(2), 629-636.
[http://dx.doi.org/10.1002/ptr.6852] [PMID: 32902005]
[84]
Lv, J.; Zhang, Y.; Tian, Z.; Liu, F.; Shi, Y.; Liu, Y.; Xia, P. Astragalus polysaccharides protect against dextran sulfate sodium-induced colitis by inhibiting NF-κB activation. Int. J. Biol. Macromol., 2017, 98, 723-729.
[http://dx.doi.org/10.1016/j.ijbiomac.2017.02.024] [PMID: 28188801]
[85]
Stronati, L.; Palone, F.; Negroni, A.; Colantoni, E.; Mancuso, A.B.; Cucchiara, S.; Cesi, V.; Isoldi, S.; Vitali, R. Dipotassium glycyrrhizate improves intestinal mucosal healing by modulating extracellular matrix remodeling genes and restoring epithelial barrier functions. Front. Immunol., 2019, 10, 939.
[http://dx.doi.org/10.3389/fimmu.2019.00939] [PMID: 31105713]
[86]
Kudo, T.; Okamura, S.; Zhang, Y.; Masuo, T.; Mori, M. Topical application of glycyrrhizin preparation ameliorates experimentally induced colitis in rats. World J. Gastroenterol., 2011, 17(17), 2223-2228.
[http://dx.doi.org/10.3748/wjg.v17.i17.2223] [PMID: 21633533]
[87]
de Putter, R.; Donck, J. Low-dose liquorice ingestion resulting in severe hypokalaemic paraparesis, rhabdomyolysis and nephrogenic diabetes insipidus. Clin. Kidney J., 2014, 7(1), 73-75.
[http://dx.doi.org/10.1093/ckj/sft159] [PMID: 25859357]
[88]
Jin, M.; Zhao, K.; Huang, Q.; Shang, P. Structural features and biological activities of the polysaccharides from Astragalus membranaceus. Int. J. Biol. Macromol., 2014, 64, 257-266.
[http://dx.doi.org/10.1016/j.ijbiomac.2013.12.002] [PMID: 24325861]
[89]
Auyeung, K.K.; Han, Q.B.; Ko, J.K. Astragalus membranaceus: A review of its protection against inflammation and gastrointestinal cancers. Am. J. Chin. Med., 2016, 44(1), 1-22.
[http://dx.doi.org/10.1142/S0192415X16500014] [PMID: 26916911]
[90]
Yang, H.; Li, Y.; Wu, W.; Sun, Q.; Zhang, Y.; Zhao, W.; Lv, H.; Xia, Q.; Hu, P.; Li, H.; Qian, J. The incidence of inflammatory bowel disease in Northern China: A prospective population-based study. PLoS One, 2014, 9(7), e101296.
[http://dx.doi.org/10.1371/journal.pone.0101296] [PMID: 25029440]
[91]
Yan, X.; Lu, Q.G.; Zeng, L.; Li, X.H.; Liu, Y.; Du, X.F.; Bai, G.M. Synergistic protection of astragalus polysaccharides and matrine against ulcerative colitis and associated lung injury in rats. World J. Gastroenterol., 2020, 26(1), 55-69.
[http://dx.doi.org/10.3748/wjg.v26.i1.55] [PMID: 31933514]
[92]
Flórez, N.; Gonzalez-Munoz, M.; Ribeiro, D.; Fernandes, E.; Dominguez, H.; Freitas, M. Algae polysaccharides’ chemical characterization and their role in the inflammatory process. Curr. Med. Chem., 2017, 24(2), 149-175.
[http://dx.doi.org/10.2174/0929867323666161028160416] [PMID: 27804878]
[93]
Rioux, J.D.; Xavier, R.J.; Taylor, K.D.; Silverberg, M.S.; Goyette, P.; Huett, A.; Green, T.; Kuballa, P.; Barmada, M.M.; Datta, L.W.; Shugart, Y.Y.; Griffiths, A.M.; Targan, S.R.; Ippoliti, A.F.; Bernard, E.J.; Mei, L.; Nicolae, D.L.; Regueiro, M.; Schumm, L.P.; Steinhart, A.H.; Rotter, J.I.; Duerr, R.H.; Cho, J.H.; Daly, M.J.; Brant, S.R. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat. Genet., 2007, 39(5), 596-604.
[http://dx.doi.org/10.1038/ng2032] [PMID: 17435756]
[94]
Xia, E.Q.; Cui, B.; Xu, X.R.; Song, Y.; Ai, X.X.; Li, H.B. Microwave-assisted extraction of oxymatrine from Sophora flavescens. Molecules, 2011, 16(9), 7391-7400.
[http://dx.doi.org/10.3390/molecules16097391] [PMID: 21878859]
[95]
Cao, X.; He, Q. Anti-tumor activities of bioactive phytochemicals in Sophora flavescens for breast cancer. Cancer Manag. Res., 2020, 12, 1457-1467.
[http://dx.doi.org/10.2147/CMAR.S243127] [PMID: 32161498]
[96]
Wen, J.B.; Zhu, F.Q.; Chen, W.G.; Jiang, L.P.; Chen, J.; Hu, Z.P.; Huang, Y.J.; Zhou, Z.W.; Wang, G.L.; Lin, H.; Zhou, S.F. Oxymatrine improves intestinal epithelial barrier function involving NF-κB-mediated signaling pathway in CCl4-induced cirrhotic rats. PLoS One, 2014, 9(8), e106082.
[http://dx.doi.org/10.1371/journal.pone.0106082] [PMID: 25171482]
[97]
Guzman, J.R.; Koo, J.S.; Goldsmith, J.R.; Mühlbauer, M.; Narula, A.; Jobin, C. Oxymatrine prevents NF-κB nuclear translocation and ameliorates acute intestinal inflammation. Sci. Rep., 2013, 3(1), 1629.
[http://dx.doi.org/10.1038/srep01629] [PMID: 23568217]
[98]
Danese, S. New therapies for inflammatory bowel disease: From the bench to the bedside. Gut, 2012, 61(6), 918-932.
[http://dx.doi.org/10.1136/gutjnl-2011-300904] [PMID: 22115827]
[99]
Qiu, M.; Liu, J.; Feng, P.; Su, Y.; Guo, R.; Shi, F.; Wang, S.; Zhao, B. Cytochrome P450s regulates aloperine-induced pathological changes in mouse liver and kidney. Res. Vet. Sci., 2020, 132, 97-100.
[http://dx.doi.org/10.1016/j.rvsc.2020.06.005] [PMID: 32544634]
[100]
Wang, R.; Deng, X.; Gao, Q.; Wu, X.; Han, L.; Gao, X.; Zhao, S.; Chen, W.; Zhou, R.; Li, Z.; Bai, C. Sophora alopecuroides L.: An ethnopharmacological, phytochemical., and pharmacological review. J. Ethnopharmacol., 2020, 248, 112172.
[http://dx.doi.org/10.1016/j.jep.2019.112172] [PMID: 31442619]
[101]
Fu, X.; Sun, F.; Wang, F.; Zhang, J.; Zheng, B.; Zhong, J.; Yue, T.; Zheng, X.; Xu, J.F.; Wang, C.Y. Aloperine protects mice against DSS‐induced colitis by PP2A‐mediated PI3K/Akt/mTOR signaling suppression. Mediators Inflamm., 2017, 2017(1), 1-14.
[http://dx.doi.org/10.1155/2017/5706152] [PMID: 29056830]
[102]
Lee, I.A.; Low, D.; Kamba, A.; Llado, V.; Mizoguchi, E. Oral caffeine administration ameliorates acute colitis by suppressing chitinase 3-like 1 expression in intestinal epithelial cells. J. Gastroenterol., 2014, 49(8), 1206-1216.
[http://dx.doi.org/10.1007/s00535-013-0865-3] [PMID: 23925589]
[103]
Senchina, D.S.; Hallam, J.E.; Kohut, M.L.; Nguyen, N.A.; Perera, M.A. Alkaloids and athlete immune function: Caffeine, theophylline, gingerol, ephedrine, and their congeners. Exerc. Immunol. Rev., 2014, 20, 68-93.
[PMID: 24974722]
[104]
Singleton, E.L.; Le, N.; Ness, G.L. Theophylline and caffeine as alternatives during an aminophylline shortage. Ann. Pharmacother., 2019, 53(3), 316-320.
[http://dx.doi.org/10.1177/1060028018806624] [PMID: 30304941]
[105]
Zhou, B.; Ma, C.; Ren, X.; Xia, T.; Li, X.; Wu, Y. Production of theophylline via aerobic fermentation of pu-erh tea using tea-derived fungi. BMC Microbiol., 2019, 19(1), 261.
[http://dx.doi.org/10.1186/s12866-019-1640-2] [PMID: 31771506]
[106]
Ghasemi-Pirbaluti, M.; Motaghi, E.; Najafi, A.; Hosseini, M.J. The effect of theophylline on acetic acid induced ulcerative colitis in rats. Biomed. Pharmacother., 2017, 90, 153-159.
[http://dx.doi.org/10.1016/j.biopha.2017.03.038] [PMID: 28351778]
[107]
Annamaraju, P.; Patel, P.; Baradhi, K.M. Pentoxifylline. In: StatPearls; StatPearls Publishing: Treasure Island, FL, 2024.
[PMID: 32644522]
[108]
Hao, Y.; Huo, J.; Wang, T.; Sun, G.; Wang, W. Chemical profiling of Coptis rootlet and screening of its bioactive compounds in inhibiting Staphylococcus aureus by UPLC-Q-TOF/MS. J. Pharm. Biomed. Anal., 2020, 180, 113089.
[http://dx.doi.org/10.1016/j.jpba.2019.113089] [PMID: 31901737]
[109]
Zhang, X.J.; Yuan, Z.W.; Qu, C.; Yu, X.T.; Huang, T.; Chen, P.V.; Su, Z.R.; Dou, Y.X.; Wu, J.Z.; Zeng, H.F.; Xie, Y.; Chen, J.N. Palmatine ameliorated murine colitis by suppressing tryptophan metabolism and regulating gut microbiota. Pharmacol. Res., 2018, 137, 34-46.
[http://dx.doi.org/10.1016/j.phrs.2018.09.010] [PMID: 30243842]
[110]
Mai, C.T.; Wu, M.M.; Wang, C.L.; Su, Z.R.; Cheng, Y.Y.; Zhang, X.J. Palmatine attenuated dextran sulfate sodium (DSS)-induced colitis via promoting mitophagy-mediated NLRP3 inflammasome inactivation. Mol. Immunol., 2019, 105, 76-85.
[http://dx.doi.org/10.1016/j.molimm.2018.10.015] [PMID: 30496979]
[111]
Bjarnason, I.; Macpherson, A.J. Delivery, safety and efficacy of 5-aminosalicylate preparations. Inflammopharmacology, 1993, 2(3), 277-287.
[http://dx.doi.org/10.1007/BF02660618]
[112]
Reyhan, E.; Irkorucu, O.; Surmelioglu, A.; Ozkara, S.; Deger, K.C.; Aziret, M.; Erdem, H.; Cetinkunar, S.; Demirturk, P.; Sehirli, A.O. Efficacy of pentoxifylline and tadalafil in rat model of ischemic colitis. J. Invest. Surg., 2014, 27(6), 349-353.
[http://dx.doi.org/10.3109/08941939.2014.971204] [PMID: 25361018]
[113]
Karatay, E.; Gül Utku, Ö.; Erdal, H.; Arhan, M.; Önal, İ.K.; İbi̇ş, M.; Eki̇nci̇, Ö.; Yilmaz Demi̇rtaş, C.; Dumlu, G.Ş. Pentoxifylline attenuates mucosal damage in an experimental model of rat colitis by modulating tissue biomarkers of inflammation, oxidative stress, and fibrosis. Turk. J. Med. Sci., 2017, 47(1), 348-356.
[http://dx.doi.org/10.3906/sag-1508-98] [PMID: 28263514]
[114]
Dorrington, A.M.; Selinger, C.P.; Parkes, G.C.; Smith, M.; Pollok, R.C.; Raine, T. The historical role and contemporary use of corticosteroids in inflammatory bowel disease. J. Crohn’s Colitis, 2020, 14(9), 1316-1329.
[http://dx.doi.org/10.1093/ecco-jcc/jjaa053] [PMID: 32170314]
[115]
Dubois-Camacho, K.; Ottum, P.A.; Franco-Muñoz, D.; De la Fuente, M.; Torres-Riquelme, A.; Díaz-Jiménez, D.; Olivares-Morales, M.; Astudillo, G.; Quera, R.; Hermoso, M.A. Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology. World J. Gastroenterol., 2017, 23(36), 6628-6638.
[http://dx.doi.org/10.3748/wjg.v23.i36.6628] [PMID: 29085208]
[116]
Kim, K.U.; Kim, J.; Kim, W.H.; Min, H.; Choi, C.H. Treatments of inflammatory bowel disease toward personalized medicine. Arch. Pharm. Res., 2021, 44(3), 293-309.
[http://dx.doi.org/10.1007/s12272-021-01318-6] [PMID: 33763844]
[117]
Sattler, L.; Hanauer, S.B.; Malter, L. Immunomodulatory agents for treatment of patients with inflammatory bowel disease (review safety of anti-TNF, anti-integrin, anti IL-12/23, JAK inhibition, sphingosine 1-phosphate receptor modulator, azathioprine/6-MP and methotrexate). Curr. Gastroenterol. Rep., 2021, 23(12), 30.
[http://dx.doi.org/10.1007/s11894-021-00829-y] [PMID: 34913108]
[118]
Cai, Z.; Wang, S.; Li, J. Treatment of inflammatory bowel disease: A comprehensive review. Front. Med., 2021, 8, 765474.
[http://dx.doi.org/10.3389/fmed.2021.765474] [PMID: 34988090]
[119]
Tominaga, K.; Sugaya, T.; Tanaka, T.; Kanazawa, M.; Iijima, M.; Irisawa, A. Thiopurines: Recent topics and their role in the treatment of inflammatory bowel diseases. Front. Pharmacol., 2021, 11, 582291.
[http://dx.doi.org/10.3389/fphar.2020.582291] [PMID: 33584261]
[120]
Herfarth, H.H. Methotrexate for inflammatory bowel diseases-new developments. Dig. Dis., 2016, 34(1-2), 140-146.
[http://dx.doi.org/10.1159/000443129] [PMID: 26981630]
[121]
Mammoser, A. Calcineurin inhibitor encephalopathy. Semin. Neurol., 2012, 32(5), 517-524.
[http://dx.doi.org/10.1055/s-0033-1334471] [PMID: 23677660]
[122]
Zhang, W.; Michalowski, C.B.; Beloqui, A. Oral delivery of biologics in inflammatory bowel disease treatment. Front. Bioeng. Biotechnol., 2021, 9, 675194.
[http://dx.doi.org/10.3389/fbioe.2021.675194] [PMID: 34150733]
[123]
Queiroz, N.S.F.; Regueiro, M. Safety considerations with biologics and new inflammatory bowel disease therapies. Curr. Opin. Gastroenterol., 2020, 36(4), 257-264.
[http://dx.doi.org/10.1097/MOG.0000000000000607] [PMID: 31895234]
[124]
Rakowsky, S.; Papamichael, K.; Cheifetz, A.S. Choosing the right biologic for complications of inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol., 2022, 16(3), 235-249.
[http://dx.doi.org/10.1080/17474124.2022.2036122] [PMID: 35094628]
[125]
Zhang, H.M.; Yuan, S.; Meng, H.; Hou, X.T.; Li, J.; Xue, J.C.; Li, Y.; Wang, Q.; Nan, J.X.; Jin, X.J.; Zhang, Q.G. Stem cell-based therapies for inflammatory bowel disease. Int. J. Mol. Sci., 2022, 23(15), 8494.
[http://dx.doi.org/10.3390/ijms23158494] [PMID: 35955628]
[126]
Kotlarz, D.; Beier, R.; Murugan, D.; Diestelhorst, J.; Jensen, O.; Boztug, K.; Pfeifer, D.; Kreipe, H.; Pfister, E.D.; Baumann, U.; Puchalka, J.; Bohne, J.; Egritas, O.; Dalgic, B.; Kolho, K.L.; Sauerbrey, A.; Buderus, S.; Güngör, T.; Enninger, A.; Koda, Y.K.L.; Guariso, G.; Weiss, B.; Corbacioglu, S.; Socha, P.; Uslu, N.; Metin, A.; Wahbeh, G.T.; Husain, K.; Ramadan, D.; Al-Herz, W.; Grimbacher, B.; Sauer, M.; Sykora, K.W.; Koletzko, S.; Klein, C. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: Implications for diagnosis and therapy. Gastroenterology, 2012, 143(2), 347-355.
[http://dx.doi.org/10.1053/j.gastro.2012.04.045] [PMID: 22549091]
[127]
Pan, X.; Li, Q.; Zhu, X.; Li, Z.; Cai, X.; Pang, R.; Ruan, G. Mechanism and therapeutic effect of umbilical cord mesenchymal stem cells in inflammatory bowel disease. Sci. Rep., 2019, 9(1), 17646.
[http://dx.doi.org/10.1038/s41598-019-54194-y] [PMID: 31776475]
[128]
Wei, H.; Liu, X.; Ouyang, C.; Zhang, J.; Chen, S.; Lu, F.; Chen, L. Complications following stem cell therapy in inflammatory bowel disease. Curr. Stem Cell Res. Ther., 2017, 12(6), 471-475.
[PMID: 28302045]
[129]
Lalu, M.M.; McIntyre, L.; Pugliese, C.; Fergusson, D.; Winston, B.W.; Marshall, J.C.; Granton, J.; Stewart, D.J. Safety of cell therapy with mesenchymal stromal cells (SafeCell): A systematic review and meta-analysis of clinical trials. PLoS One, 2012, 7(10), e47559.
[http://dx.doi.org/10.1371/journal.pone.0047559] [PMID: 23133515]
[130]
Gough, E.; Shaikh, H.; Manges, A.R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis., 2011, 53(10), 994-1002.
[http://dx.doi.org/10.1093/cid/cir632] [PMID: 22002980]
[131]
Guo, B.; Harstall, C.; Louie, T.; Veldhuyzen van Zanten, S.; Dieleman, L.A. Systematic review: Faecal transplantation for the treatment of Clostridium difficile ‐associated disease. Aliment. Pharmacol. Ther., 2012, 35(8), 865-875.
[http://dx.doi.org/10.1111/j.1365-2036.2012.05033.x] [PMID: 22360412]
[132]
Colman, R.J.; Rubin, D.T. Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis. J. Crohn’s Colitis, 2014, 8(12), 1569-1581.
[http://dx.doi.org/10.1016/j.crohns.2014.08.006] [PMID: 25223604]
[133]
Weingarden, A.R.; Vaughn, B.P. Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease. Gut Microbes, 2017, 8(3), 238-252.
[http://dx.doi.org/10.1080/19490976.2017.1290757] [PMID: 28609251]
[134]
Büning, J.; Homann, N.; von Smolinski, D.; Borcherding, F.; Noack, F.; Stolte, M.; Kohl, M.; Lehnert, H.; Ludwig, D. Helminths as governors of inflammatory bowel disease. Gut, 2008, 57(8), 1182-1183.
[http://dx.doi.org/10.1136/gut.2008.152355] [PMID: 18628388]
[135]
Summers, R.W.; Elliott, D.E.; Qadir, K.; Urban, J.F.; Thompson, R.; Weinstock, J.V. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am. J. Gastroenterol., 2003, 98(9), 2034-2041.
[http://dx.doi.org/10.1111/j.1572-0241.2003.07660.x]
[136]
Hunter, M.M.; Mckay, D.M. Helminths as therapeutic agents for inflammatory bowel disease. Aliment. Pharmacol. Ther., 2004, 19(2), 167-177.
[http://dx.doi.org/10.1111/j.0269-2813.2004.01803.x] [PMID: 14723608]
[137]
Bemelman, W.A.; Adamina, M.; Buskens, C. DHoore, A.; Kotze, P.G.; Oresland, T.; Panis, Y.; Samprieto, G.; Spinelli, A.; Tulchinsky, H.; Warusavitarne, J.; Zmora, O. Evolving role of IBD surgery. J. Crohn’s Colitis, 2018, 12(8), 1005-1007.
[http://dx.doi.org/10.1093/ecco-jcc/jjy056]
[138]
Kühn, F.; Klar, E. Surgical principles in the treatment of ulcerative colitis. Viszeralmedizin, 2015, 31(4), 246-250.
[PMID: 26557832]
[139]
Herlihy, N.; Feakins, R. Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease? United Eur. Gastroenterol. J., 2022, 10(5), 451-464.
[http://dx.doi.org/10.1002/ueg2.12242] [PMID: 35633273]
[140]
Kiesler, P.; Fuss, I.J.; Strober, W. Experimental models of inflammatory bowel diseases. Cell. Mol. Gastroenterol. Hepatol., 2015, 1(2), 154-170.
[http://dx.doi.org/10.1016/j.jcmgh.2015.01.006] [PMID: 26000334]
[141]
Shen, Z.H.; Zhu, C.X.; Quan, Y.S.; Yang, Z.Y.; Wu, S.; Luo, W.W.; Tan, B.; Wang, X.Y. Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J. Gastroenterol., 2018, 24(1), 5-14.
[http://dx.doi.org/10.3748/wjg.v24.i1.5] [PMID: 29358877]
[142]
Zhang, Y.J.; Li, S.; Gan, R.Y.; Zhou, T.; Xu, D.P.; Li, H.B. Impacts of gut bacteria on human health and diseases. Int. J. Mol. Sci., 2015, 16(4), 7493-7519.
[http://dx.doi.org/10.3390/ijms16047493] [PMID: 25849657]
[143]
Nascimento, R.P.; Machado, A.P.F.; Galvez, J.; Cazarin, C.B.B.; Maróstica Junior, M.R. Ulcerative colitis: Gut microbiota, immunopathogenesis and application of natural products in animal models. Life Sci., 2020, 378, 118129.
[http://dx.doi.org/10.1016/j.lfs.2020.118129] [PMID: 32717271]
[144]
Wang, L.; Gao, M.; Kang, G.; Huang, H. The potential role of phytonutrients flavonoids influencing gut microbiota in the prophylaxis and treatment of inflammatory bowel disease. Front. Nutr., 2021, 8, 798038.
[http://dx.doi.org/10.3389/fnut.2021.798038] [PMID: 34970585]
[145]
Alrafas, H.R.; Busbee, P.B.; Nagarkatti, M.; Nagarkatti, P.S. Resveratrol modulates the gut microbiota to prevent murine colitis development through induction of Tregs and suppression of Th17 cells. J. Leukoc. Biol., 2019, 106(2), 467-480.
[http://dx.doi.org/10.1002/JLB.3A1218-476RR] [PMID: 30897248]
[146]
Wu, X.; Wang, L.; Tang, L.; Wang, L.; Cao, S.; Wu, Q.; Zhang, Z.; Li, L. Salvianolic acid B alters the gut microbiota and mitigates colitis severity and associated inflammation. J. Funct. Foods, 2018, 46, 312-319.
[http://dx.doi.org/10.1016/j.jff.2018.04.068]
[147]
Cheng, H.; Liu, J.; Zhang, D.; Wang, J.; Tan, Y.; Feng, W.; Peng, C. Ginsenoside Rg1 alleviates acute ulcerative colitis by modulating gut microbiota and microbial tryptophan metabolism. Front. Immunol., 2022, 13, 817600.
[http://dx.doi.org/10.3389/fimmu.2022.817600] [PMID: 35655785]
[148]
Ji, J.; Ge, X.; Chen, Y.; Zhu, B.; Wu, Q.; Zhang, J.; Shan, J.; Cheng, H.; Shi, L. Daphnetin ameliorates experimental colitis by modulating microbiota composition and Treg/Th17 balance. FASEB J., 2019, 33(8), 9308-9322.
[http://dx.doi.org/10.1096/fj.201802659RR] [PMID: 31145641]
[149]
Yuan, S.; Li, Y.; Li, J.; Xue, J.C.; Wang, Q.; Hou, X.T.; Meng, H.; Nan, J.X.; Zhang, Q.G. Traditional Chinese medicine and natural products: Potential approaches for inflammatory bowel disease. Front. Pharmacol., 2022, 13, 892790.
[http://dx.doi.org/10.3389/fphar.2022.892790] [PMID: 35873579]
[150]
Zhang, J.; Lei, H.; Hu, X.; Dong, W. Hesperetin ameliorates DSS-induced colitis by maintaining the epithelial barrier via blocking RIPK3/MLKL necroptosis signaling. Eur. J. Pharmacol., 2020, 873, 172992.
[http://dx.doi.org/10.1016/j.ejphar.2020.172992] [PMID: 32035144]
[151]
Araki, Y.; Mukaisyo, K.; Sugihara, H.; Fujiyama, Y.; Hattori, T. Increased apoptosis and decreased proliferation of colonic epithelium in dextran sulfate sodium-induced colitis in mice. Oncol. Rep., 2010, 24(4), 869-874.
[http://dx.doi.org/10.3892/or.2010.869] [PMID: 20811666]
[152]
Wu, Z.; Huang, S.; Li, T.; Li, N.; Han, D.; Zhang, B.; Xu, Z.Z.; Zhang, S.; Pang, J.; Wang, S.; Zhang, G.; Zhao, J.; Wang, J. Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis. Microbiome, 2021, 9(1), 184.
[http://dx.doi.org/10.1186/s40168-021-01115-9] [PMID: 34493333]
[153]
Liu, C.; Zeng, Y.; Wen, Y.; Huang, X.; Liu, Y. Natural products modulate cell apoptosis: A promising way for the treatment of ulcerative colitis. Front. Pharmacol., 2022, 13, 806148.
[http://dx.doi.org/10.3389/fphar.2022.806148] [PMID: 35173617]
[154]
Yousef, M.; Pichyangkura, R.; Soodvilai, S.; Chatsudthipong, V.; Muanprasat, C. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: Therapeutic efficacy and possible mechanisms of action. Pharmacol. Res., 2012, 66(1), 66-79.
[http://dx.doi.org/10.1016/j.phrs.2012.03.013] [PMID: 22475725]
[155]
Hou, C.; Chen, L.; Yang, L.; Ji, X. An insight into anti-inflammatory effects of natural polysaccharides. Int. J. Biol. Macromol., 2020, 153, 248-255.
[http://dx.doi.org/10.1016/j.ijbiomac.2020.02.315] [PMID: 32114173]
[156]
Paunovic, V.; Harnett, M.M. Mitogen-activated protein kinases as therapeutic targets for rheumatoid arthritis. Drugs, 2013, 73(2), 101-115.
[http://dx.doi.org/10.1007/s40265-013-0014-6] [PMID: 23371304]
[157]
Zhu, L.; Shen, H.; Gu, P.Q.; Liu, Y.J.; Zhang, L.; Cheng, J.F. Baicalin alleviates TNBS induced colitis by inhibiting PI3K/AKT pathway activation. Exp. Ther. Med., 2020, 20(1), 581-590.
[http://dx.doi.org/10.3892/etm.2020.8718] [PMID: 32537016]
[158]
Yuan, D.; Li, C.; Huang, Q.; Fu, X.; Dong, H. Current advances in the anti-inflammatory effects and mechanisms of natural polysaccharides. Crit. Rev. Food Sci. Nutr., 2023, 63(22), 5890-5910.
[http://dx.doi.org/10.1080/10408398.2022.2025535] [PMID: 35021901]
[159]
El-Akabawy, G.; El-Sherif, N.M. Zeaxanthin exerts protective effects on acetic acid-induced colitis in rats via modulation of pro-inflammatory cytokines and oxidative stress. Biomed. Pharmacother., 2019, 111, 841-851.
[http://dx.doi.org/10.1016/j.biopha.2019.01.001] [PMID: 30616083]
[160]
Grzybowska-Chlebowczyk, U.; Wysocka-Wojakiewicz, P.; Jasielska, M.; Cukrowska, B.; Więcek, S.; Kniażewska, M.; Chudek, J. Oxidative and antioxidative stress status in children with inflammatory bowel disease as a result of a chronic inflammatory process. Mediators Inflamm., 2018, 2018(1), 1-7.
[http://dx.doi.org/10.1155/2018/4120973] [PMID: 30116148]
[161]
Piechota-Polanczyk, A.; Fichna, J. Review article: The role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. Naunyn Schmiedebergs Arch. Pharmacol., 2014, 387(7), 605-620.
[http://dx.doi.org/10.1007/s00210-014-0985-1] [PMID: 24798211]
[162]
Zhu, X.; Tian, X.; Yang, M.; Yu, Y.; Zhou, Y.; Gao, Y.; Zhang, L.; Li, Z.; Xiao, Y.; Moses, R.E.; Li, X.; Zhang, B. Procyanidin B2 promotes intestinal injury repair and attenuates colitis-associated tumorigenesis via suppression of oxidative stress in mice. Antioxid. Redox Signal., 2021, 35(2), 75-92.
[http://dx.doi.org/10.1089/ars.2019.7911] [PMID: 32940048]
[163]
Lv, T.; Shen, L.; Yang, L.; Diao, W.; Yang, Z.; Zhang, Y.; Yu, S.; Li, Y. Polydatin ameliorates dextran sulfate sodium-induced colitis by decreasing oxidative stress and apoptosis partially via sonic hedgehog signaling pathway. Int. Immunopharmacol., 2018, 64, 256-263.
[http://dx.doi.org/10.1016/j.intimp.2018.09.009] [PMID: 30218952]
[164]
Sangaraju, R.; Nalban, N.; Alavala, S.; Rajendran, V.; Jerald, M.K.; Sistla, R. Protective effect of galangin against dextran sulfate sodium (DSS)-induced ulcerative colitis in Balb/c mice. Inflamm. Res., 2019, 68(8), 691-704.
[http://dx.doi.org/10.1007/s00011-019-01252-w] [PMID: 31147743]
[165]
Wang, Y.; Ji, X.; Yan, M.; Chen, X.; Kang, M.; Teng, L.; Wu, X.; Chen, J.; Deng, C. Protective effect and mechanism of polysaccharide from Dictyophora indusiata on dextran sodium sulfate-induced colitis in C57BL/6 mice. Int. J. Biol. Macromol., 2019, 140, 973-984.
[http://dx.doi.org/10.1016/j.ijbiomac.2019.08.198] [PMID: 31449863]
[166]
Silva, F.A.R.; Rodrigues, B.L.; Ayrizono, M.L.S.; Leal, R.F. The immunological basis of inflammatory bowel disease. Gastroenterol. Res. Pract., 2016, 2016(1), 1-11.
[http://dx.doi.org/10.1155/2016/2097274] [PMID: 28070181]
[167]
Zaiatz Bittencourt, V.; Jones, F.; Doherty, G.; Ryan, E.J. Targeting immune cell metabolism in the treatment of inflammatory bowel disease. Inflamm. Bowel Dis., 2021, 27(10), 1684-1693.
[http://dx.doi.org/10.1093/ibd/izab024] [PMID: 33693743]
[168]
Zhu, Y.; Zhao, Q.; Huang, Q.; Li, Y.; Yu, J.; Zhang, R.; Liu, J.; Yan, P.; Xia, J.; Guo, L.; Liu, G.; Yang, X.; Zeng, J. Nuciferine regulates immune function and gut microbiota in DSS-induced ulcerative colitis. Front. Vet. Sci., 2022, 9, 939377.
[http://dx.doi.org/10.3389/fvets.2022.939377] [PMID: 35909691]
[169]
Li, M.; Guo, W.; Dong, Y.; Wang, W.; Tian, C.; Zhang, Z.; Yu, T.; Zhou, H.; Gui, Y.; Xue, K.; Li, J.; Jiang, F.; Sarapultsev, A.; Wang, H.; Zhang, G.; Luo, S.; Fan, H.; Hu, D. Beneficial effects of celastrol on immune balance by modulating gut microbiota in experimental ulcerative colitis mice. Genomics Proteomics Bioinformatics, 2022, 20(2), 288-303.
[http://dx.doi.org/10.1016/j.gpb.2022.05.002] [PMID: 35609771]
[170]
Wei, B.; Zhang, R.; Zhai, J.; Zhu, J.; Yang, F.; Yue, D.; Liu, X.; Lu, C.; Sun, X. Suppression of Th17 cell response in the alleviation of dextran sulfate sodium-induced colitis by Ganoderma lucidum polysaccharides. J. Immunol. Res., 2018, 2018(1), 1-10.
[http://dx.doi.org/10.1155/2018/2906494] [PMID: 29888292]
[171]
Zhu, H.; Li, Y.R. Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: Updated experimental and clinical evidence. Exp. Biol. Med., 2012, 237(5), 474-480.
[http://dx.doi.org/10.1258/ebm.2011.011358] [PMID: 22442342]
[172]
Scott, O.; Roifman, C.M. NF-κB pathway and the Goldilocks principle: Lessons from human disorders of immunity and inflammation. J. Allergy Clin. Immunol., 2019, 143(5), 1688-1701.
[http://dx.doi.org/10.1016/j.jaci.2019.03.016] [PMID: 30940520]
[173]
Cui, L.; Wang, W.; Luo, Y.; Ning, Q.; Xia, Z.; Chen, J.; Feng, L.; Wang, H.; Song, J.; Tan, X.; Tan, W.; Wang, C.; Jia, X. Polysaccharide from Scutellaria baicalensis Georgi ameliorates colitis via suppressing NF-κB signaling and NLRP3 inflammasome activation. Int. J. Biol. Macromol., 2019, 132, 393-405.
[http://dx.doi.org/10.1016/j.ijbiomac.2019.03.230] [PMID: 30936012]
[174]
Liu, C.; Dunkin, D.; Lai, J.; Song, Y.; Ceballos, C.; Benkov, K.; Li, X.M. Anti-inflammatory effects of Ganoderma lucidum triterpenoid in human crohn’s disease associated with downregulation of NF-κB signaling. Inflamm. Bowel Dis., 2015, 21(8), 1918-1925.
[http://dx.doi.org/10.1097/MIB.0000000000000439] [PMID: 25993687]
[175]
Zhou, Y.; Zhong, B.; Min, X.; Hou, Y.; Lin, L.; Wu, Q.; Shi, J.; Chen, X. Therapeutic potential of isobavachalcone, a natural flavonoid, in murine experimental colitis by inhibiting NF‐κB p65. Phytother. Res., 2021, 35(10), 5861-5870.
[http://dx.doi.org/10.1002/ptr.7246] [PMID: 34435401]
[176]
Liu, M.; Zhang, G.; Zheng, C.; Song, M.; Liu, F.; Huang, X.; Bai, S.; Huang, X.; Lin, C.; Zhu, C.; Hu, Y.; Mi, S.; Liu, C. Activating the pregnane X receptor by imperatorin attenuates dextran sulphate sodium‐induced colitis in mice. Br. J. Pharmacol., 2018, 175(17), 3563-3580.
[http://dx.doi.org/10.1111/bph.14424] [PMID: 29945292]
[177]
Villarino, A.V.; Kanno, Y.; O’Shea, J.J. Mechanisms and consequences of Jak–STAT signaling in the immune system. Nat. Immunol., 2017, 18(4), 374-384.
[http://dx.doi.org/10.1038/ni.3691] [PMID: 28323260]
[178]
Zhang, X.; Xu, F.; Liu, L.; Feng, L.; Wu, X.; Shen, Y.; Sun, Y.; Wu, X.; Xu, Q. (+)-Borneol improves the efficacy of edaravone against DSS-induced colitis by promoting M2 macrophages polarization via JAK2-STAT3 signaling pathway. Int. Immunopharmacol., 2017, 53, 1-10.
[http://dx.doi.org/10.1016/j.intimp.2017.10.002] [PMID: 29028547]
[179]
Tao, J.H.; Duan, J.A.; Zhang, W.; Jiang, S.; Guo, J.M.; Wei, D.D. Polysaccharides from Chrysanthemum morifolium Ramat ameliorate colitis rats via regulation of the metabolic profiling and NF-κ B/TLR4 and IL-6/JAK2/STAT3 signaling pathways. Front. Pharmacol., 2018, 9, 746.
[http://dx.doi.org/10.3389/fphar.2018.00746] [PMID: 30042683]
[180]
Direito, R.; Rocha, J.; Lima, A.; Gonçalves, M.M.; Duarte, M.P.; Mateus, V.; Sousa, C.; Fernandes, A.; Pinto, R.; Boavida Ferreira, R.; Sepodes, B.; Figueira, M.E. Reduction of inflammation and colon injury by a spearmint phenolic extract in experimental bowel disease in mice. Medicines, 2019, 6(2), 65.
[http://dx.doi.org/10.3390/medicines6020065] [PMID: 31174376]
[181]
Zhu, F.; Zheng, J.; Xu, F.; Xi, Y.; Chen, J.; Xu, X. Resveratrol alleviates dextran sulfate sodium-induced acute ulcerative colitis in mice by mediating PI3K/Akt/VEGFA pathway. Front. Pharmacol., 2021, 12, 693982.
[http://dx.doi.org/10.3389/fphar.2021.693982] [PMID: 34497510]
[182]
Hu, L.H.; Liu, J.Y.; Yin, J.B. Eriodictyol attenuates TNBS ‐induced ulcerative colitis through repressing TLR4/NF‐kB signaling pathway in rats. Kaohsiung J. Med. Sci., 2021, 37(9), 812-818.
[http://dx.doi.org/10.1002/kjm2.12400] [PMID: 34042266]
[183]
El-Sherbiny, M.; Eisa, N.H.; Abo El-Magd, N.F.; Elsherbiny, N.M.; Said, E.; Khodir, A.E. Anti-inflammatory/anti-apoptotic impact of betulin attenuates experimentally induced ulcerative colitis: An insight into TLR4/NF-kB/caspase signalling modulation. Environ. Toxicol. Pharmacol., 2021, 88, 103750.
[http://dx.doi.org/10.1016/j.etap.2021.103750] [PMID: 34597787]
[184]
Wang, Y.J.; Li, Q.M.; Zha, X.Q.; Luo, J.P. Dendrobium fimbriatum hook polysaccharide ameliorates dextran-sodium-sulfate-induced colitis in mice via improving intestinal barrier function, modulating intestinal microbiota, and reducing oxidative stress and inflammatory responses. Food Funct., 2022, 13(1), 143-160.
[http://dx.doi.org/10.1039/D1FO03003E] [PMID: 34874039]
[185]
Venkataraman, B.; Ojha, S.; Belur, P.D.; Bhongade, B.; Raj, V.; Collin, P.D.; Adrian, T.E.; Subramanya, S.B. Phytochemical drug candidates for the modulation of peroxisome proliferator‐activated receptor γ in inflammatory bowel diseases. Phytother. Res., 2020, 34(7), 1530-1549.
[http://dx.doi.org/10.1002/ptr.6625] [PMID: 32009281]
[186]
Dubuquoy, L.; Rousseaux, C.; Thuru, X.; Peyrin-Biroulet, L.; Romano, O.; Chavatte, P.; Chamaillard, M.; Desreumaux, P. PPAR as a new therapeutic target in inflammatory bowel diseases. Gut, 2006, 55(9), 1341-1349.
[http://dx.doi.org/10.1136/gut.2006.093484] [PMID: 16905700]
[187]
Venkataraman, B.; Almarzooqi, S.; Raj, V.; Alhassani, A.T.; Alhassani, A.S.; Ahmed, K.J.; Subramanian, V.S.; Ojha, S.K.; Attoub, S.; Adrian, T.E.; Subramanya, S.B. Thymoquinone, a dietary bioactive compound, exerts anti-inflammatory effects in colitis by stimulating expression of the colonic epithelial PPAR-γ transcription factor. Nutrients, 2021, 13(4), 1343.
[http://dx.doi.org/10.3390/nu13041343] [PMID: 33920708]
[188]
Venkataraman, B.; Almarzooqi, S.; Raj, V.; Dudeja, P.K.; Bhongade, B.A.; Patil, R.B.; Ojha, S.K.; Attoub, S.; Adrian, T.E.; Subramanya, S.B. α-Bisabolol Mitigates Colon Inflammation by Stimulating Colon PPAR-γ Transcription Factor: In Vivo and In Vitro Study. PPAR Res., 2022, 2022(1), 1-22.
[http://dx.doi.org/10.1155/2022/5498115] [PMID: 35465355]
[189]
Xu, B.; Huang, S.; Chen, Y.; Wang, Q.; Luo, S.; Li, Y.; Wang, X.; Chen, J.; Luo, X.; Zhou, L. Synergistic effect of combined treatment with baicalin and emodin on DSS ‐induced colitis in mouse. Phytother. Res., 2021, 35(10), 5708-5719.
[http://dx.doi.org/10.1002/ptr.7230] [PMID: 34379340]
[190]
Zhou, Y.; Wang, D.; Yan, W. Treatment effects of natural products on inflammatory bowel disease in vivo and their mechanisms: Based on animal experiments. Nutrients, 2023, 15(4), 1031.
[http://dx.doi.org/10.3390/nu15041031] [PMID: 36839389]
[191]
Duan, L.; Cheng, S.; Li, L.; Liu, Y.; Wang, D.; Liu, G. Natural anti-inflammatory compounds as drug candidates for inflammatory bowel disease. Front. Pharmacol., 2021, 12, 684486.
[http://dx.doi.org/10.3389/fphar.2021.684486] [PMID: 34335253]

Rights & Permissions Print Cite
Article Metrics
23
2
Wayfinder Image
© 2026 Bentham Science Publishers | Privacy Policy